Symptoms and Transmission of SARS-CoV-2 Among Children - Utah and Wisconsin, March-May 2020.


Journal

Pediatrics
ISSN: 1098-4275
Titre abrégé: Pediatrics
Pays: United States
ID NLM: 0376422

Informations de publication

Date de publication:
01 2021
Historique:
accepted: 30 09 2020
pubmed: 10 10 2020
medline: 14 1 2021
entrez: 9 10 2020
Statut: ppublish

Résumé

Limited data exist on severe acute respiratory syndrome coronavirus 2 in children. We described infection rates and symptom profiles among pediatric household contacts of individuals with coronavirus disease 2019. We enrolled individuals with coronavirus disease 2019 and their household contacts, assessed daily symptoms prospectively for 14 days, and obtained specimens for severe acute respiratory syndrome coronavirus 2 real-time reverse transcription polymerase chain reaction and serology testing. Among pediatric contacts (<18 years), we described transmission, assessed the risk factors for infection, and calculated symptom positive and negative predictive values. We compared secondary infection rates and symptoms between pediatric and adult contacts using generalized estimating equations. Among 58 households, 188 contacts were enrolled (120 adults; 68 children). Secondary infection rates for adults (30%) and children (28%) were similar. Among households with potential for transmission from children, child-to-adult transmission may have occurred in 2 of 10 (20%), and child-to-child transmission may have occurred in 1 of 6 (17%). Pediatric case patients most commonly reported headache (79%), sore throat (68%), and rhinorrhea (68%); symptoms had low positive predictive values, except measured fever (100%; 95% confidence interval [CI]: 44% to 100%). Compared with symptomatic adults, children were less likely to report cough (odds ratio [OR]: 0.15; 95% CI: 0.04 to 0.57), loss of taste (OR: 0.21; 95% CI: 0.06 to 0.74), and loss of smell (OR: 0.29; 95% CI: 0.09 to 0.96) and more likely to report sore throat (OR: 3.4; 95% CI: 1.04 to 11.18). Children and adults had similar secondary infection rates, but children generally had less frequent and severe symptoms. In two states early in the pandemic, we observed possible transmission from children in approximately one-fifth of households with potential to observe such transmission patterns.

Sections du résumé

BACKGROUND AND OBJECTIVES
Limited data exist on severe acute respiratory syndrome coronavirus 2 in children. We described infection rates and symptom profiles among pediatric household contacts of individuals with coronavirus disease 2019.
METHODS
We enrolled individuals with coronavirus disease 2019 and their household contacts, assessed daily symptoms prospectively for 14 days, and obtained specimens for severe acute respiratory syndrome coronavirus 2 real-time reverse transcription polymerase chain reaction and serology testing. Among pediatric contacts (<18 years), we described transmission, assessed the risk factors for infection, and calculated symptom positive and negative predictive values. We compared secondary infection rates and symptoms between pediatric and adult contacts using generalized estimating equations.
RESULTS
Among 58 households, 188 contacts were enrolled (120 adults; 68 children). Secondary infection rates for adults (30%) and children (28%) were similar. Among households with potential for transmission from children, child-to-adult transmission may have occurred in 2 of 10 (20%), and child-to-child transmission may have occurred in 1 of 6 (17%). Pediatric case patients most commonly reported headache (79%), sore throat (68%), and rhinorrhea (68%); symptoms had low positive predictive values, except measured fever (100%; 95% confidence interval [CI]: 44% to 100%). Compared with symptomatic adults, children were less likely to report cough (odds ratio [OR]: 0.15; 95% CI: 0.04 to 0.57), loss of taste (OR: 0.21; 95% CI: 0.06 to 0.74), and loss of smell (OR: 0.29; 95% CI: 0.09 to 0.96) and more likely to report sore throat (OR: 3.4; 95% CI: 1.04 to 11.18).
CONCLUSIONS
Children and adults had similar secondary infection rates, but children generally had less frequent and severe symptoms. In two states early in the pandemic, we observed possible transmission from children in approximately one-fifth of households with potential to observe such transmission patterns.

Identifiants

pubmed: 33033178
pii: peds.2020-027268
doi: 10.1542/peds.2020-027268
pii:
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2021 by the American Academy of Pediatrics.

Déclaration de conflit d'intérêts

POTENTIAL CONFLICT OF INTEREST: The authors have indicated they have no potential conflicts of interest to disclose.

Auteurs

Rebecca L Laws (RL)

COVID-19 Response Team, lxq2@cdc.gov.
Contributed equally as co-first authors.

Rebecca J Chancey (RJ)

COVID-19 Response Team.
Contributed equally as co-first authors.

Elizabeth M Rabold (EM)

COVID-19 Response Team.
Epidemic Intelligence Service, and.

Victoria T Chu (VT)

COVID-19 Response Team.
Epidemic Intelligence Service, and.

Nathaniel M Lewis (NM)

COVID-19 Response Team.
Epidemic Intelligence Service, and.
Utah Department of Health, Salt Lake City, Utah.

Mark Fajans (M)

COVID-19 Response Team.

Hannah E Reses (HE)

COVID-19 Response Team.

Lindsey M Duca (LM)

COVID-19 Response Team.
Epidemic Intelligence Service, and.

Patrick Dawson (P)

COVID-19 Response Team.
Epidemic Intelligence Service, and.

Erin E Conners (EE)

COVID-19 Response Team.

Radhika Gharpure (R)

COVID-19 Response Team.
Epidemic Intelligence Service, and.

Sherry Yin (S)

COVID-19 Response Team.

Sean Buono (S)

COVID-19 Response Team.
Laboratory Leadership Service, Centers for Disease Control and Prevention, Atlanta, Georgia.

Mary Pomeroy (M)

COVID-19 Response Team.
Epidemic Intelligence Service, and.

Anna R Yousaf (AR)

COVID-19 Response Team.
Epidemic Intelligence Service, and.

Daniel Owusu (D)

COVID-19 Response Team.
Epidemic Intelligence Service, and.

Ashutosh Wadhwa (A)

COVID-19 Response Team.
Laboratory Leadership Service, Centers for Disease Control and Prevention, Atlanta, Georgia.

Eric Pevzner (E)

COVID-19 Response Team.

Katherine A Battey (KA)

COVID-19 Response Team.

Henry Njuguna (H)

COVID-19 Response Team.

Victoria L Fields (VL)

COVID-19 Response Team.
Epidemic Intelligence Service, and.

Phillip Salvatore (P)

COVID-19 Response Team.
Epidemic Intelligence Service, and.

Michelle O'Hegarty (M)

COVID-19 Response Team.

Jeni Vuong (J)

COVID-19 Response Team.

Christopher J Gregory (CJ)

COVID-19 Response Team.

Michelle Banks (M)

COVID-19 Response Team.

Jared Rispens (J)

COVID-19 Response Team.
Epidemic Intelligence Service, and.

Elizabeth Dietrich (E)

COVID-19 Response Team.

Perrine Marcenac (P)

COVID-19 Response Team.
Epidemic Intelligence Service, and.

Almea Matanock (A)

COVID-19 Response Team.

Ian Pray (I)

COVID-19 Response Team.
Epidemic Intelligence Service, and.
Wisconsin Department of Health Services, Madison, Wisconsin.

Ryan Westergaard (R)

Wisconsin Department of Health Services, Madison, Wisconsin.

Trivikram Dasu (T)

City of Milwaukee Health Department, Milwaukee, Wisconsin.

Sanjib Bhattacharyya (S)

City of Milwaukee Health Department, Milwaukee, Wisconsin.

Ann Christiansen (A)

North Shore Health Department, Milwaukee, Wisconsin.

Lindsey Page (L)

City of Milwaukee Health Department, Milwaukee, Wisconsin.

Angela Dunn (A)

Utah Department of Health, Salt Lake City, Utah.

Robyn Atkinson-Dunn (R)

Utah Department of Health, Salt Lake City, Utah.

Kim Christensen (K)

Utah Department of Health, Salt Lake City, Utah.

Tair Kiphibane (T)

Salt Lake County Health Department, Salt Lake City, Utah; and.

Sarah Willardson (S)

Davis County Health Department, Clearfield, Utah.

Garrett Fox (G)

COVID-19 Response Team.

Dongni Ye (D)

COVID-19 Response Team.

Scott A Nabity (SA)

COVID-19 Response Team.

Alison Binder (A)

COVID-19 Response Team.

Brandi D Freeman (BD)

COVID-19 Response Team.
Laboratory Leadership Service, Centers for Disease Control and Prevention, Atlanta, Georgia.

Sandra Lester (S)

COVID-19 Response Team.

Lisa Mills (L)

COVID-19 Response Team.

Natalie Thornburg (N)

COVID-19 Response Team.

Aron J Hall (AJ)

COVID-19 Response Team.

Alicia M Fry (AM)

COVID-19 Response Team.

Jacqueline E Tate (JE)

COVID-19 Response Team.

Cuc H Tran (CH)

COVID-19 Response Team.

Hannah L Kirking (HL)

COVID-19 Response Team.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH